Frank Westermann, 9amHealth co-CEO

Cigna backs a GLP-1 pre­scrib­ing start­up, adding new ven­ture funds to 9amHealth

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

Cigna’s ven­ture unit just made a bet on a start­up fo­cused on car­diometa­bol­ic con­di­tions that wants to play a role in pre­scrib­ing GLP-1 med­ica­tions.

9amHealth said on Tues­day it raised $9.5 mil­lion in a Se­ries A ex­ten­sion led by The Cigna Group Ven­tures. It adds to $16 mil­lion from the Se­ries A raised in April 2022 by the start­up, which pro­vides vir­tu­al vis­its, pre­scrip­tions and lab tests re­lat­ed to con­di­tions like hy­per­ten­sion, type 2 di­a­betes and weight man­age­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.